Drug Research
Veranova and Phorum.AI Partner to Deliver Generative AI Chemistry Optimization to the Pharmaceutical & Biotech Industry
Veranova and Phorum.AI announced that they are collaborating on next-generation optimization of pharmaceutical manufacturing processes using artificial intelligence (AI)
Building on years of research and experimentation by Phorum.AI co-founder and MIT Professor of Chemistry, Brad Pentelute, Phorum.AI is deploying generative...
Drug Research
Singapore To Be Home To $1.5bn AstraZeneca Production Plant
On May 20, 2024, AstraZeneca, the global biopharma company, announced plans to build a $1.5 billion manufacturing facility in Singapore. With this announcement, the company is looking to start the design and construction of the new Singapore setup by...
Drug Research
Laboratory-Developed Tests Set To Be Regulated By The FDA
The FDA’s final rule that solidifies its presence and authority on Laboratory-Developed Tests- LDTs goes on to mark a prominent shift in the regulation as far as the diagnostics sector is concerned.
The rule very well makes it pretty clear...
Drug Research
AbbVie, Gilgamesh Pharma Partner on Next-Gen Psychiatric Therapies
AbbVie and Gilgamesh Pharmaceuticals entered a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise in psychiatry and Gilgamesh's research platform to discover novel neuroplastogens.
Under the agreement, the companies have agreed...
Drug Research
Fulcrum Enters Collaboration & License Agreement with Sanofi
Fulcrum Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing small molecules, has entered into a collaboration and license agreement with Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of...
Drug Research
Aldevron, Acuitas Partner to Expand Capabilities in mRNA LNP Encapsulation
Aldevron, a global manufacturer of DNA, RNA, and proteins used in cell and gene therapies and vaccine development, has entered a strategic partnership with Acuitas Therapeutics, Inc., a private biotechnology company specializing in the development of delivery systems for...
Drug Research
Abzena Launches EpiScreen 2.0, a Next Generation Immunogenicity Tool for De-Risking the Development of Complex Biologics and Bioconjugates
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of preclinical immunogenicity in protein, antibody, and gene...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
